{"id":"flu-v","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Pain, redness, or swelling at the injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by introducing a small, harmless piece of the influenza virus to the body, which triggers an immune response and helps protect against future infections.","oneSentence":"FLU-v is an inactivated influenza vaccine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:54:40.406Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention"}]},"trialDetails":[{"nctId":"NCT05864118","phase":"NA","title":"Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2023-08-21","conditions":"Respiratory Tract Infections","enrollment":1000},{"nctId":"NCT01024400","phase":"PHASE2","title":"Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-11","conditions":"Influenza","enrollment":110},{"nctId":"NCT07248319","phase":"NA","title":"Production and Evaluation of an Evidence-based Health Awareness Video on Precautionary Measures Against Respiratory Infectious Diseases (HAV-RID Study)","status":"NOT_YET_RECRUITING","sponsor":"Lebanese American University","startDate":"2026-03-01","conditions":"Produce and Evaluate an Evidence-based Health Awareness Video","enrollment":160},{"nctId":"NCT01063608","phase":"PHASE4","title":"Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff.","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-10","conditions":"Influenza A Virus, H1N1 Subtype","enrollment":147},{"nctId":"NCT04896086","phase":"PHASE1","title":"First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-24","conditions":"Influenza, Seasonal Influenza","enrollment":63},{"nctId":"NCT03694392","phase":"","title":"Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2018-09-16","conditions":"Influenza, Pneumonia, Lower Respiratory Tract Infection","enrollment":2776278},{"nctId":"NCT05567783","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A","status":"TERMINATED","sponsor":"Vir Biotechnology, Inc.","startDate":"2022-10-30","conditions":"Influenza A","enrollment":2977},{"nctId":"NCT05642078","phase":"PHASE3","title":"Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-02-18","conditions":"Prevention of Influenza","enrollment":2550},{"nctId":"NCT04363359","phase":"PHASE2","title":"Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2020-01-15","conditions":"Influenza","enrollment":1980},{"nctId":"NCT05389137","phase":"PHASE4","title":"To Identify the Immunogenicity and Safety of QIV in Children Aged 3-8 Years","status":"UNKNOWN","sponsor":"Wuhan Institute of Biological Products Co., Ltd","startDate":"2022-03-02","conditions":"Influenza","enrollment":360},{"nctId":"NCT01051661","phase":"PHASE3","title":"Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-12","conditions":"Influenza","enrollment":6154},{"nctId":"NCT02962908","phase":"PHASE2","title":"A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine","status":"COMPLETED","sponsor":"PepTcell Limited","startDate":"2016-08","conditions":"Influenza","enrollment":175},{"nctId":"NCT03180801","phase":"PHASE2","title":"Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model","status":"COMPLETED","sponsor":"PepTcell Limited","startDate":"2016-08-18","conditions":"Influenza","enrollment":153},{"nctId":"NCT02467842","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-10","conditions":"Influenza","enrollment":1503},{"nctId":"NCT01003288","phase":"NA","title":"Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen","status":"COMPLETED","sponsor":"University of Bergen","startDate":"2009-10","conditions":"Healthy","enrollment":255},{"nctId":"NCT00430521","phase":"PHASE2","title":"Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-05","conditions":"Influenza, Influenza Vaccines","enrollment":512},{"nctId":"NCT03784885","phase":"PHASE2","title":"A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult","status":"COMPLETED","sponsor":"Advagene Biopharma Co. Ltd.","startDate":"2017-09-01","conditions":"Influenza Infection","enrollment":345},{"nctId":"NCT01161160","phase":"PHASE2","title":"Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Influenza","enrollment":209},{"nctId":"NCT01059617","phase":"PHASE1","title":"Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-09","conditions":"Influenza","enrollment":133},{"nctId":"NCT00985673","phase":"PHASE2","title":"Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-01","conditions":"Influenza","enrollment":611},{"nctId":"NCT01155037","phase":"PHASE2","title":"Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults","status":"COMPLETED","sponsor":"Oswaldo Cruz Foundation","startDate":"2010-03","conditions":"HIV Infection","enrollment":450},{"nctId":"NCT01755364","phase":"PHASE3","title":"A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old","status":"COMPLETED","sponsor":"Adimmune Corporation","startDate":"2012-11-01","conditions":"Influenza","enrollment":122},{"nctId":"NCT01759654","phase":"PHASE3","title":"A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects","status":"COMPLETED","sponsor":"Adimmune Corporation","startDate":"2012-10-24","conditions":"Influenza","enrollment":120},{"nctId":"NCT03016143","phase":"PHASE2","title":"Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)","status":"COMPLETED","sponsor":"Research Institute for Biological Safety Problems","startDate":"2016-10","conditions":"Influenza","enrollment":300},{"nctId":"NCT00979602","phase":"PHASE3","title":"Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-09","conditions":"Influenza","enrollment":4048},{"nctId":"NCT00985088","phase":"PHASE2","title":"Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-11","conditions":"Influenza","enrollment":1343},{"nctId":"NCT00976820","phase":"PHASE2","title":"Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-20","conditions":"Influenza","enrollment":323},{"nctId":"NCT01039220","phase":"NA","title":"Incidence of H1N1v Influenza-like Illness and Risk Factors for Serious Influenza Forms in HIV Infected Patients","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-12","conditions":"HIV Infections, Influenza","enrollment":1266},{"nctId":"NCT03028116","phase":"PHASE1","title":"Reactogenicity, Safety and Immunogenicity Study of a Allantoic Split Inactivated Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"Research Institute for Biological Safety Problems","startDate":"2016-05","conditions":"Influenza, Human","enrollment":44},{"nctId":"NCT00976469","phase":"PHASE1, PHASE2","title":"A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2009-09","conditions":"Influenza, Pandemic Influenza","enrollment":400},{"nctId":"NCT02148328","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2014-05","conditions":"Influenza","enrollment":240},{"nctId":"NCT01024725","phase":"","title":"Evaluation of Pandemic Vaccination Campaign","status":"COMPLETED","sponsor":"Finnish Institute for Health and Welfare","startDate":"2009-11","conditions":"Influenza Caused by the Novel A(H1N1)v Influenza Virus","enrollment":3518},{"nctId":"NCT01617239","phase":"PHASE1","title":"Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2012-06","conditions":"Influenza","enrollment":84},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningitis, Meningococcal","enrollment":4545},{"nctId":"NCT01229397","phase":"PHASE3","title":"Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2010-10","conditions":"Influenza","enrollment":205},{"nctId":"NCT01310400","phase":"PHASE3","title":"Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2009-10","conditions":"Influenza","enrollment":1356},{"nctId":"NCT01631110","phase":"PHASE3","title":"Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2012-07","conditions":"Influenza","enrollment":110},{"nctId":"NCT01303510","phase":"PHASE4","title":"A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains for the Northern Hemisphere","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2008-07","conditions":"Influenza","enrollment":111},{"nctId":"NCT01306253","phase":"PHASE4","title":"A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern Hemisphere","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2009-06","conditions":"Influenza","enrollment":114},{"nctId":"NCT01306305","phase":"PHASE4","title":"A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2010/2011 Influenza Virus Strains for the Northern Hemisphere","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2010-06","conditions":"Influenza","enrollment":110},{"nctId":"NCT01229371","phase":"PHASE3","title":"Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2010-10","conditions":"Influenza","enrollment":440},{"nctId":"NCT01893177","phase":"PHASE3","title":"Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2013-07","conditions":"Influenza","enrollment":110},{"nctId":"NCT00912496","phase":"PHASE1","title":"Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-06","conditions":"Influenza","enrollment":637},{"nctId":"NCT00391768","phase":"PHASE1, PHASE2","title":"Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-01","conditions":"Influenza","enrollment":87},{"nctId":"NCT00513669","phase":"PHASE1","title":"Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania","status":"COMPLETED","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2008-01","conditions":"Falciparum Malaria","enrollment":50},{"nctId":"NCT01457027","phase":"PHASE4","title":"A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza Season","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2011-10","conditions":"Influenza","enrollment":52},{"nctId":"NCT01226758","phase":"PHASE1","title":"Influenza Vaccine Challenge Study in Healthy Subjects","status":"COMPLETED","sponsor":"PepTcell Limited","startDate":"2010-06","conditions":"Influenza","enrollment":32},{"nctId":"NCT01008813","phase":"PHASE2","title":"Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-10","conditions":"HIV Infections","enrollment":306},{"nctId":"NCT01063933","phase":"PHASE1, PHASE2","title":"Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Influenza","enrollment":""},{"nctId":"NCT01181336","phase":"PHASE1","title":"Phase 1b Influenza Vaccine Study in Healthy Subjects","status":"COMPLETED","sponsor":"PepTcell Limited","startDate":"2010-04","conditions":"Influenza","enrollment":48},{"nctId":"NCT00724997","phase":"PHASE1","title":"Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers","status":"COMPLETED","sponsor":"AVIR Green Hills Biotechnology AG","startDate":"2007-03","conditions":"Seasonal Human Influenza","enrollment":48},{"nctId":"NCT01017172","phase":"PHASE4","title":"Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients","status":"UNKNOWN","sponsor":"Goethe University","startDate":"2009-11","conditions":"HIV-1 Infection, Cancer, Immunosuppression","enrollment":500},{"nctId":"NCT00731029","phase":"PHASE3","title":"Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-09","conditions":"Influenza","enrollment":239}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"FLU-v","genericName":"FLU-v","companyName":"PepTcell Limited","companyId":"peptcell-limited","modality":"Biologic","firstApprovalDate":"","aiSummary":"FLU-v is an inactivated influenza vaccine. Used for Influenza prevention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}